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Background: Exacerbations of asthma and COPD are triggered by rhinoviruses. Uncontrolled inflammatory
pathways, pathogenic bacterial burden and impaired antiviral immunity are thought to be important factors in dis-
ease severity and duration. Macrolides including azithromycin are often used to treat the above diseases, but exhibit
variable levels of efficacy. Inhaled corticosteroids are also readily used in treatment, butmay lack specificity. Ideally,
new treatment alternatives should suppress unwanted inflammation, but spare beneficial antiviral immunity.
Methods: In the present study, we screened 225 novel macrolides and tested them for enhanced antiviral activity
against rhinovirus, as well as anti-inflammatory activity and activity against Gram-positive and Gram-negative bac-
teria. Primary bronchial epithelial cells were grown from 10 asthmatic individuals and the effects of macrolides on
rhinovirus replication were also examined. Another 30 structurally similar macrolides were also examined.
Results: The oleandomycin derivative Mac5, compared with azithromycin, showed superior induction (up to 5-fold,
EC50¼5–11 mM) of rhinovirus-induced type I IFNb, type III IFNl1 and type III IFNl2/3 mRNA and the IFN-stimu-
lated genes viperin andMxA, yet had no effect on IL-6 and IL-8mRNA.Mac5 also suppressed rhinovirus replication at
48 h, proving antiviral activity. Mac5 showed antibacterial activity against Gram-positive Streptococcus pneumoniae;
however, it did not have anyantibacterial properties comparedwith azithromycinwhen used against Gram-negative
Escherichia coli (as a model organism) and also the respiratory pathogens Pseudomonas aeruginosa and non-type-
able Haemophilus influenzae. Further non-toxic Mac5 derivatives were identified with various anti-inflammatory,
antiviral and antibacterial activities.
Conclusions: The data support the idea thatmacrolides have antiviral properties through amechanism that is yet to
be ascertained. We also provide evidence that macrolides can be developed with anti-inflammatory, antibacterial
and antiviral activity and show surprising versatility depending on the clinical need.
Introduction
Type I and type III IFNs are antiviral cytokines made by a wide
range of cells in response to virus infection and ligation of various
pattern recognition receptors (PRRs). Type I IFNas and IFNb signal
via the IFNa receptor (IFNAR)-1 and IFNAR2 complex, while type
III IFNls (also designated IL-29, IL-28A and IL-28B in humans)
act via the IL-10Rb and IFNl1Ra chains.1 Type I and type III
IFN production are one of the first initiators of the host’s innate
immunity against virus infection2 and induces the ‘antiviral’
state. IFNs are known to initiate the expression of .300 different
genes termed IFN-inducible genes (ISGs), via signalling through
the type I and type III IFN signalling complexes,3 –6 and many
of the protein products of these ISGs have been shown to be dir-
ectly antiviral in a range of models.7 ISGs can be extracellular,
such as chemokines or cytokines that attract other cells of the
immune system, or IFNs themselves with a classical example
being IFNb inducing IFNa and IFNls.8 Most ISGs, however, are
intracellular proteins that act to prevent virus protein trafficking,
virus RNA synthesis or virion assembly and release. Viperin and
MxA are two examples of intracellular antiviral ISGs.9,10 Viperin
is thought to act on viral protein and also lipid trafficking within
the host cell,11,12 whilst MxA is a small GTPase that localizes to
the endoplasmic reticulum and inhibits viral replication.13
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Several specific ISGs have been shown to be directly antiviral in
models of respiratory virus infection, including influenza virus,14
respiratory syncytial virus and human rhinovirus (RV).15
Studies by Wark and colleagues in 2005 and later by Contoli
et al. in 2006 initially described deficiencies in the ability of
asthmatic primary human bronchial epithelial cells (BECs) to pro-
duce type I and type III IFNs in response to RV infection.16,17
Subsequent studies have confirmed the role for deficient IFN pro-
duction in asthmatic BECs cultured from both children and
adults.18–20 Studies have also been extended to other cell types
including airway macrophages16,21 and peripheral blood-derived
dendritic cells.22,23 Impaired type I and type III IFN production
have also been observed in cells derived from patients with
COPD.24 This growing body of evidence suggests that augmenting
deficient IFN production in response to RV infection in asthmatic
and COPD patients could be a novel target for therapeutic inter-
vention in the context of RV-associated asthma and COPD
exacerbations.
Currently, there are no therapies that attempt to restore defi-
cient IFN levels in the treatment of asthma; however, recently,
inhaled recombinant IFNb therapy has been used in a Phase II
clinical trial examining naturally occurring infections in a cohort
of mild–moderate asthmatics.25 Encouragingly, in a subset of
patients, IFNb therapy reduced symptoms and improved lung
function recovery time post-infection compared with placebo.
Apart from respiratory diseases, IFN therapy is currently a main-
stay in the treatment of viral hepatitis, used in combination with
the antiviral agent ribavirin.26 Increases in host IFN production
have been shown to directly translate into antiviral activity in a
clinical context.27 Due to the expense associated with using
recombinant IFNs as biological interventions in human disease,
one alternative approach is small molecule agonists of IFNs or
their associated antiviral pathways that illicit the same IFN-
mediated protective effect.
The aim of this study was to identify one or more novel macro-
lides with antiviral-augmenting ability that had similar or greater
potency or efficacy to that of azithromycin. The antiviral effects of
azithromycin shown in previous studies in healthy BECs and cystic
fibrosis (CF) BECs were both modest and variable, producing up to
200%–500% augmentation of type I and type III IFN induction
following RV infection, but with limited potency in vitro.28,29 We
therefore embarked on a screen of 225 novel macrolides in an
attempt to identify compounds with stronger effects on innate
host responses to RV in terms of both efficacy and potency. We
thus report the identification of a novel macrolide, Mac5, that
could augment primary BEC gene expression of RV-induced
IFNb and IFNls and the ISGs MxA and viperin. Mac5 was also
able to decrease RV replication in BECs. This augmentation of
antiviral activity was up to 5-fold superior to that seen with
azithromycin treatment. Mac5, however, showed no inhibition
of Escherichia coli, Pseudomonas aeruginosa or non-typeable
Haemophilus influenzae (NTHi) growth, but did suppress the
growth of Streptococcus pneumoniae. We then further assessed
30 novel analogues of Mac5 and identified further macrolides
with similar antiviral efficacy, but with improved anti-inflammatory
and/or antibacterial properties. Importantly, the data overall
show that antiviral, IFN-mediated pathways can be targeted inde-
pendently of inflammation and that macrolides represent an
exciting and versatile class of drug for the treatment of exacerba-
tions of chronic airway diseases.
Materials and methods
Macrolides
Azithromycin (Sigma–Aldrich, USA), 225 novel macrolides and 30 further
macrolides based around the Mac5 structure (Pfizer UK) were obtained as
dry powders and made up in 70% EtOH. Azithromycin (Sigma–Aldrich)
and all novel macrolide compounds (Pfizer, USA) were prepared as 0.1 M
solutions by adding the appropriate amount of 70% EtOH to the macro-
lide, vortexing for ≥10 s and sonicating in a water bath for up to 3 min
to ensure complete dissolution. Stock solutions were kept at 2208C.
Cells and viruses
All cell cultures were maintained in a humidified 378C incubator with 5%
CO2 (New Brunswick, USA). BECs were maintained in fully supplemented
BEC growth medium (BEGM) (Lonza). Culture medium was aspirated and
replaced with fresh medium every 48 h. HeLa cells were maintained in
DMEM supplemented with 10% heat-inactivated FBS (PAA, UK), 2% 1 M
HEPES (Gibco, USA) and 1% NaHCO3 (Gibco). BEAS-2B cells were main-
tained in RPMI medium supplemented with 10% heat-inactivated FBS,
2% 1 M HEPES and 1% NaHCO3. Major group RV16 and minor group
RV1b were cultured in HeLa cells as previously described30 and identity
confirmed using serotype-specific antibodies and titration in HeLa cells.
The RV1b stock was Mycoplasma-free and stored at 2808C.
Primary BEC culture from commercial sources
Human BECs (Lonza) were split according to the supplier’s recommended
protocol. When cells reached 90% confluency, the culture medium was
removed and the cell monolayer rinsed twice with 4 mL of HEPES-buffered
saline solution per flask (Lonza); the final rinsewas completely aspirated to
ensure total removal of cell culture medium. Next, 2 mL of trypsin/EDTA
(Lonza) was added to each flask and flasks were agitated by hand to
ensure complete coverage of the cell monolayer. Flasks were then incu-
bated at 378C (5% CO2) for 3 min. Flasks were tapped by hand firmly
and detached cells were removed and added directly to 4 mL of trypsin-
neutralizing solution (TNS; Lonza) per flask. A further 1 mL of trypsin/
EDTA was added to flasks to remove stubbornly adherent cells and
returned to the incubator for 1 min, after which each flask was thoroughly
rinsed with 4 mL of TNS and the cell solution pooled. The cell solution was
then centrifuged at 1200 rpm for 6 min and the supernatant discarded.
The cells were thoroughly resuspended in 10 mL of fully supplemented
BEGM; this solution was then split between fresh 75 cm2 flasks and the
total volume was made up to 10 mL per flask. Routinely, two flasks
(from thawing) were split into nine and grown to 90% confluency. For
experiments, three of those flasks were split into nine more, while cells
from the remaining six flaskswere counted and seeded onto culture plates
at a density of 0.5×105 cells/mL in fully supplemented BEGM for all experi-
ments. Cells were not grown beyond six passages.
Culture of asthmatic BECs from bronchial brushings
Bronchial brushings were obtained via bronchoscopy of atopic, poorly con-
trolled asthmatics as previously described.31 Cells were dislodged and
grown until confluency and passaged as previously described.20,31 All
experiments were performed with cells at p2, as described below.
Treatment of cells with azithromycin and novel
macrolides
Working concentrations of eachmacrolide (100–0.78 mM)were generated
by thoroughly thawing the stock solutions in a 378Cwater bath for 10 min,
vortexing for 10 s and diluting the stock into the appropriate volume of
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serum/supplement-free medium. Working solutions were then vortexed
and added to cell culture wells. To normalize for effects of vehicle, a vol-
ume of 70% EtOH diluted in medium equal to that of the top dose of
macrolide solution in each experiment was used to dilute the other solu-
tions and was also added onto cells and included as a ‘vehicle control’. All
treatments were for 24 h prior to RV infection. In certain experiments, cell
viability after 24 h of macrolide treatment was assessed by an MTT assay
(Sigma–Aldrich) according to themanufacturer’s recommended protocol.
Infection of BEAS-2B cells and BECs with RVs
Prior to infection, all cells were placed in infection medium (BECs in
supplement-free bronchial epithelial basal medium and BEAS-2Bs in
RPMI with 2% FBS) for 24 h. Stock RV1b was diluted in the relevant infec-
tion medium prior to application to cell cultures to give an approximate
moi of 1. RV was then added (200 mL per well of a 12-well plate or
50 mL for a 48-well plate) and cultures were incubated at room tempera-
ture for 1 h with agitation. Virus was then removed and the cultures were
washed three times with infection medium. Cultures were placed in infec-
tion medium and incubated for a specified amount of time at 378C.
Transfection of BEAS-2B cells and reporter
screening assay
Superfect (Qiagen) was used for all transfections, according to the manu-
facturer’s recommended protocol. Transfections were performed in
48-well culture plates (Nunc). Stock plasmids were at 1 mg/mL and stored
at2808C. An initial mastermix of reporter plasmid (IFNb-Luc or IFNl1-Luc
grown in-house, 0.2 mg/well) was diluted in serum-free RPMI an internal
control vector (Renilla, 0.05 mg/well) making a total of 0.25 mg/well DNA.
Reporter assay
Relative light units (RLU) were measured using a luminometer with
Promega’s Dual Luciferase kit (Promega, USA) according to the manufac-
turer’s instructions. Relative promoter activity was calculated by dividing
the RLU of the reporter plasmid (IFNb-Luc or IFNl1-Luc) by the RLU of
the internal control vector (Renilla). To assess any augmentation of pro-
moter activity, relative promoter activity was then expressed as a percent-
age of RV-induced promoter activity (RV induction being 100%).
RNA extraction, cDNA synthesis and quantitative PCR
Supernatants from cell cultures were removed and 350 mL of RLT (Qiagen)
buffer was added to each culture well. Cells were lysed and stored at
2808C. All RNA extractions were performed using RNeasy (Qiagen) kits
according to the manufacturer’s instructions. RNA was eluted by adding
42 mL of RNA-free H2O and centrifuging at 14000 rpm for 1 min. RNA
was converted into cDNA using an Omniscript RT kit (Qiagen) according
to the manufacturer’s instructions, in a total reaction volume of 60 mL.
Each mixture was incubated at 378C for 60 min and frozen at 2808C
until used. Quantification of mRNA copy numbers was measured by
TaqMan PCR (7500 Fast Real-Time PCR System; Applied Biosystems, USA).
Each PCR mixture contained 6.25 mL of QuantiTect Probe PCR Master Mix
(Qiagen), sense and antisense primers and an optimized ratio 175 nM
probe and 1 mL of unknown or standard cDNA. Concentrations of primers
and sequences of primers and probes are as previously reported.28 The
quantitative PCR cycling program was as follows: 508C for 2 min, 948C
for 10 min followed by amplification cycles of 948C for 15 s and 608C for
15 s to a total of 45 cycles. An eight-point standard curve was used to
determine mRNA copy number in unknown samples. Standards were
diluted in nuclease-free H2O to the top standard of 10
7 copies/mL; sequen-
tial 1:10 dilutions were produced to 100 copies/mL.
ELISA
ELISAwas used to quantify IL-6 and IFNl1 (IL-29) from cell culture super-
natants using the manufacturer’s recommended protocol (R&D Systems,
USA). Absorbance at 450 nm was measured using a SpectraMax Plus
(Molecular Devices, USA) ELISA plate reader and absorbance levels were
determined by extrapolation of a four-parameter standard curve gener-
ated in SoftMax Pro software (Molecular Devices). Detection limits for
the assays were: IL-6, 15 pg/mL; IL-8, 15 pg/mL; and IFNl1, 30 pg/mL.
Antibacterial assay using E. coli culture
Initially, E. coli (Invitrogen, UK) from frozen glycerol stocks was plated out
using aseptic techniques onto LB agar plates and incubated at 378C for
24 h. An individual colony was picked and grown in liquid LB overnight at
378Cwith agitation to allow the bacteria to reach log-phase growth. From
this starter culture, a 1:100 dilutionwasmade into freshmedium contain-
ing macrolides or vehicle control and incubated for up to 12 h at 378Cwith
agitation. Sequential sampling of cultures was performed at specific time-
points and analysed by spectrometry at OD600.
Antibacterial assay using respiratory pathogens
S. pneumoniae strain D39was grown from a glycerol stock (1:200 dilution)
for 16 h with shaking (150 rpm) at 378C with 5% CO2 in the presence or
absence or each macrolide (50 mM) or vehicle. Single colonies of P. aerugi-
nosa strain PAO1 were resuspended in LB broth and grown overnight at
378C with shaking at 200 rpm. Overnight cultures were diluted 1:100 in
fresh LB broth in 96-well culture plates and macrolides (50 mM) or vehicle
added. Plates were incubated at 378C with shaking at 200 rpm for 4 h.
Each macrolide was tested in triplicate. NTHi strain R2866 was grown as
a starter culture overnight at 378C in 5% CO2 with shaking at 200 rpm.
This was then diluted 1:100 in fresh BHI broth in the presence or absence
of eachmacrolide or vehicle control for 4 h. Sampling of each bacterial cul-
turewas performed at the specified timepoints and analysed by spectrom-
etry at OD600.
Statistical analysis
For data pertaining to gene or protein expression by cultured normal BECs,
the mean and SEM were displayed in all graphs. Gene and protein expres-
sion datawere normalized to percentage over induction by positive control
(where the positive control was expressed as 100%). As the data were not
normally distributed, a one-way Kruskal–Wallis non-parametric analysis
with Dunn’s comparison was used to assess significance between groups.
Data from time course experiments were analysed by two-way analysis of
variance (ANOVA) with Bonferroni’s post-test. Data from dose–response
assays were analysed using non-linear regression on a sigmoidal dose–
response curve to generate EC50 and R
2 values. Two-tailed Spearman cor-
relation analysis was employed where stated. For bacterial growth curves,
the AUC was calculated and analysed by ANOVA with Bonferroni’s
post-test. All statistical analysis employed a CI of 95%. P values of
,0.05 were considered statistically significant.
Results
Optimization of a screening assay using IFN promoter
reporter constructs to identify antiviral properties of
novel macrolides
We first used the human IFNb promoter (Figure S1, available as
Supplementary data at JAC Online) as a reporter gene to screen
225 novel macrolides. Our aim was to identify novel macrolides
with IFN-augmenting properties greater than azithromycin and
New macrolides with IFN-augmenting potential
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so we decided on a three-phase screening programme (summar-
ized in Figure S1 and Table S1). Phase 1 was a quick screen (n¼1)
using reporter assays to determine the highest responders com-
pared with both RV1b infection alone and also with RV1b infection
with azithromycin (positive control). Phase 2 was further confirm-
ation of these hits by three repeats with the IFNb promoter and
also the IFNl1 promoter reporter assays, which is activated by a
similar mechanism to IFNb.8,32,33 Phase 3 was the final validation
of the selected hits, by several experiments in primary BECs and
assessment of effects on endogenous RV-induced IFN and ISG
mRNA expression.
Screening assays revealed 15 novel macrolides with
IFN-augmenting activity
Results of phase 1 of the screening process are shown in Figure 1.
A number of novelmacrolides gave induction of the RV1b-induced
IFNb reporter equal to or greater than that of azithromycin, while
somemacrolides completely suppressed IFNb promoter induction
and were not studied further. Some compounds were toxic at the
50 mM dose used and were reassessed at 10 mM and found to
have no effect on RV1b-induced IFNb promoter induction (data
not shown). Compounds that were toxic at both 50 and 10 mM
were not studied further. Figure 1 shows therewere 15macrolides
that had ≥1.5-fold-induction+3×SD better than that seen with
azithromycin and were progressed into the next phase of screen-
ing. The results of the second phase are shown in Figure 2. The top
15 hits were repeated three times in both the IFNb promoter and
the IFNl1 promoter assay. The data show that Mac5, Mac26,
Mac162, Mac202 and Mac206 all produced approximately
.200% induction of RV1b-induced promoter activation, which
was equal to or greater than seen with azithromycin and RV1b.
These five also showed significant induction versus RV1b and
vehicle for IFNb (Figure 2a) and showed similar, but non-significant,
induction for the IFNl1 promoter (Figure 2b). The induction of the
IFNb and IFNl1 promoters was similar for all 15 hits and induction
of both reporters for all 15 hits correlated positively (Figure 2c).
The 15 novelmacrolideswith IFN-augmenting activity are
derivatives of azithromycin, erythromycin and
oleandomycin
The 15 novel macrolides identified in the IFN assays belonged to
three classes ofmacrolides. Mac26, Mac132, Mac153 andMac183
were derivatives of azithromycin, Mac162, Mac202, Mac206,
Mac39, Mac122 and Mac185 were derivatives of erythromycin
and Mac2, Mac5, Mac12, Mac14 and Mac51 were derivatives of
oleandomycin. How each class of macrolide compared during
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Figure 1. Novel macrolides differentially augmented RV1b-induced IFNb promoter activity in BEAS-2B cells. (a) BEAS-2B cell cultures were treated with
50 mM of novel macrolide compounds (1–115) for 24 h prior to RV1b infection for 24 h. Seven compounds (light grey bars) augmented IFNb promoter
activity 1.5-fold above the level of azithromycin (dark grey bar). Compounds that were toxic at 50 mM were excluded. (b) BEAS-2B cell cultures were
treated with 50 mM of novel macrolide compounds (116–225) for 24 h prior to RV1b infection for 24 h. Eight compounds (light grey bars)
augmented IFNb promoter activity 1.5-fold above the level of azithromycin (dark grey bar). Compounds that were toxic at 50 mM were excluded.
Data expressed as percentage of RV1b+vehicle (VEH; black bars; 100%). n¼1.
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phase 2 of the screening is shown in Figure S2. While azithromycin
and erythromycin derivatives gave more robust inductions of
IFNb, IFNl1 and combined IFNb and IFNl1 promoter induction,
there was no significant difference between each of the three
classes.
Structural description of the top five selected macrolides
Structures of the top five selected macrolides are shown in
Figure 3. Stereochemistry has been included where possible.
Cellular toxicity studies showed that each macrolide was not
toxic by MTT assay (Figure S3). They belong to three classes of
macrolides: azithromycin, erythromycin and oleandomycin.
For comparison, the parental compounds are also shown.
Mac26 was found to be an azithromycin analogue (Figure 3a),
Mac162, Mac202 and Mac206 are erythromycin analogues
(Figure 3b) and Mac5 is an oleandomycin analogue (Figure 3c).
Azithromycin is a 15-membered macrocyclic ring containing a
methyl-substituted nitrogen atom. Mac26 differs from the paren-
tal azithromycin in three ways: the two hydroxyl groups at posi-
tions C12 and C13 are cyclized into a carbonate; the cladinose
sugar has been replaced by a nitrobenzoyl group; and on the des-
osamine sugar, the hydroxyl at position C2 has been converted
into an acetate. Erythromycin is another 14-memberedmacrolide
very similar to azithromycin, but lacks the nitrogen atom in the
macrocyclic ring. The three erythromycin derivatives identified in
the screen show extensive modifications from the parental com-
pound. Mac162 exhibited a substitution of the ketone moiety for
an aminopyrimidine at C9 of the macrocyclic ring. Mac202 con-
tains a cyclic thiocarbonate group in place of the C9 ketone.
Mac206 possesses an unsaturated ketone and a 2-methyl-4-
amidothiazole substituent on the cladinose sugar. Oleandomycin
is a 14-membered macrolide with the two sugars oleandrose and
desosamine. Mac5 differs from oleandomycin by the acetate at
C11 of the 14-membered macrocyclic ring and the addition of a
tolyl urea at position C4 of the oleandrose ring.
Oleandomycin derivative Mac5 induced endogenous type
I and type III IFN and ISG transcription, but not
pro-inflammatory cytokines, in primary BECs
As we identified five novel macrolides that could augment
RV-induced IFNb and IFNl1 promoter activation in a cell line,
we next sought to confirm these findings with endogenous
gene expression using commercially available, primary BECs
(phase 3). We found that of all five macrolides, Mac5 was the
only consistent performer significantly augmenting IFNb, IFNl1,
IFNl2/3 and viperin, while showing increased trends of induction
compared with vehicle-treated RV1b-infected controls for MxA
mRNA (Figure 4). The mean augmentation of IFN or ISG mRNA
was 1000% compared with vehicle-treated RV1b-infected
cells, but had a wide range (500%–2800%). No other macrolide
gave significant induction versus vehicle-treated RV1b-infected
cells and no macrolide including Mac5 induced IFN of ISGs spon-
taneously in the absence of infection (Figure 4). Furthermore,
comparisons with azithromycin-treated RV1b-infected cells in
the same experiments showed that Mac5 gave higher levels of
induction for all mRNAs measured; however, none was signifi-
cantly greater than levels of mRNA induction compared with
azithromycin (Figure 4). At best, Mac5 was 5-fold better at aug-
menting RV-induced viperin mRNA compared with azithromycin,
but was mostly 2–3-fold more effective than azithromycin for
most genes at the same dose. We also checked induction of
MxA and viperin protein by western blotting for each macrolide
with RV1b infection (Figure S4) and found that Mac5 robustly
induced viperin protein and gave a modest induction of MxA
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Figure 2. Novel macrolides augmented RV1b-induced IFNb and IFNl1
promoter activity. (a) Five novel macrolides significantly augmented
RV1b-induced IFNb promoter activity in BEAS-2B cell cultures. (b) Five
novel macrolides showed trends for augmenting IFNl1 activity, although
none to a significant level. (c) BEAS-2B cell cultures treated with novel
macrolides and subsequently infected with RV1b exhibited a strong
correlation between levels of IFNb promoter activity and IFNl1 promoter
activity. Data expressed as percentage change of RV1b+vehicle (VEH)
induction. *P,0.05, **P,0.01 and ***P,0.001 versus RV1b+VEH. n¼3.
Correlations assessed by Spearman correlation. NS, not significant.
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relative to RV1b-infected cells. Mac26 and Mac206 also showed
induction of viperin protein relative to RV1b. Consistent with the
mRNA data, no macrolide in the absence of infection induced
MxA or viperin protein. Further studies showed that Mac5 gave sig-
moidal dose–response curves and augmented RV-induced IFN
and ISGs in a dose-dependent manner with EC50s ranging from
5 to 11 mM (Figure 5). In comparison, the dose–response curves
of azithromycin for the same genes were not sigmoidal, indicating
a different relationship between dose and effect studied
(Figure S5). A complete comparison between Mac5 and azithro-
mycin is shown in Table S2. Mac5 also did not significantly aug-
ment RV-induced IL-6 or IL-8 mRNA (Figure S6) or affect the
basal transcription of these genes (data not shown).
Mac5 reduced RV1B replication in primary healthy BECs
and asthmatic BECs
We next assessed the ability of Mac5 to reduce RV replication
(Figure 6), reasoning that a robust IFN response would translate
into reductions in virus load at later timepoints. We found that
in commercially available, healthy normal BECs, Mac5 signifi-
cantly reduced RV1b load at 48 h post-infection by 64%
(Figure 6a), but was not significantly better than azithromycin,
which showed a modest, non-significant reduction of RV release
of 50%. We also assessed the effects of Mac5 in BECs derived
from adult poorly controlled asthmatics (clinical details presented
in Table S3). Mac5 did not significantly reduce RV16 (Figure 6b), but
significantly reduced RV1b (Figure 6c) replication at 48 h in the
asthmatic BECs. Overall, 7/10 subjects showed decreases in
both RV16 and RV1b release compared with vehicle-treated cells.
Mac5 possessed limited antibacterial activity
We also wanted to compare the antibacterial properties of each of
the five novelmacrolideswith azithromycin.We found that none of
the five macrolides had antibacterial properties compared with
azithromycin using E. coli growth as a model (Figure 7a). Mac5
and all othermacrolides failed to reduce E. coli growth at any time-
point (1–8 h) and all were significantly different fromazithromycin
by AUC analysis, which totally prevented E. coli growth (Figure 7a).
However, Mac5, Mac162, Mac202, Mac206 and azithromycin
all displayed antibacterial activity against the Gram-positive bac-
terium S. pneumoniae culture at 16 h, while Mac26 did not
(Figure 7b). Similar to the findings with E. coli, no novel macrolide
suppressed growth of the Gram-negative respiratory pathogens
P. aeruginosa at 4 h (Figure 7c) and NTHi at 4 h (Figure 7d).
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Hit expansion around the Mac5 structure identified
several oleandomycin derivatives with IFN-augmenting,
anti-inflammatory and antibacterial activity
A further 30 4′′-ureido-oleandomycin derivatives related to Mac5
were screened from the Pfizer compound collection (synthesis of
these compounds is described in Patent US409899334). These 30
derivatives of Mac5 were first assessed for IFN-augmenting activ-
ity using a reporter system (Figure 8a). We found that only Mac5R
and Mac5AC significantly induced IFNb promoter activity with
RV1b relative to vehicle, while several showed non-significant
trends for induction. Mac5M appeared to reduce IFNb reporter
activity. Several compounds showed anti-inflammatory activity
using the IL-6 promoter reporter (Figure 8b), with the parental
Mac5 and derivatives Mac5K, Mac5M, Mac5Y and Mac5AB signifi-
cantly reducing activity relative to vehicle. Other compounds
exhibited non-significant trends for reduction. We next assessed
each compound in the antibacterial assays, using S. pneumoniae,
P. aeruginosa, NTHi and E. coli.We found that all Mac5 derivatives
suppressed S. pneumoniae growth, although not all gave signifi-
cant reductions compared with vehicle (Figure 9a). Results for
the Gram-negatives were more variable. Again, no macrolide
could suppress growth of P. aeruginosa (Figure 9b), while Mac5A,
Mac5B, Mac5I, Mac5M, Mac5U, Mac5V, Mac5Y, Mac5AC and
Mac5AD all had significant activity against NHTi (Figure 9c).
E. coli was also examined and Mac5B, Mac5A, Mac5AC and
Mac5M significantly inhibited E. coli relative to vehicle, while
Mac5H, Mac5Y and Mac5AD showed greater suppression that
was also significant versus vehicle (Figure S7). All other Mac5
derivatives had no effect on E. coli growth (data not shown).
Each of the three properties is depicted in Figure S7, with anti-
inflammatory activity (IL-6 promoter) and antiviral activity
(IFNb promoter) plotted against each other. Anti-inflammatory
and antiviral activity were not significantly related (Spearman cor-
relation r¼20.1272, P¼0.5825). Cellular toxicity assays using the
MTT assay showed that the above macrolides were not toxic in
BEAS-2B cells (Figure S8).
Structural description of Mac5-like oleandomycin
derivatives
The 30 derivatives differed in substitution of the urea and generally
fall within the following classes: (i) direct phenyl ureas; (ii) benzyl/
methylene heterocyclic ureas; and (iii) acyl ureas (Figure 10, stereo-
chemistry has been included). One interesting trend is that Mac5,
Mac5K, Mac5M, Mac5Y and Mac5AB significantly reduced RV1b-
induced IL-6 promoter activation and contain both phenyl and
benzyl ureas, but only a subset of the benzyl ureas inhibited the
growth of Gram-negative NHTi and E. coli compared with vehicle
(those being Mac5A, Mac5B, Mac5H, Mac5M, Mac5Y, Mac5AC and
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in normal BEC cultures. Mac26, Mac162 andMac202 failed to significantly augmentmRNA levels of IFNb. (b) Mac5 andMac206 augmented IFNl1mRNA
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Figure 5. Mac5 showed a dose-dependent augmentation of type I and type III IFN mRNA in normal BECs. (a) Mac5 was titrated 1:2 and showed a
sigmoidal dose–response to augmenting RV1b-induced IFNb mRNA at 24 h post-infection. (b) Mac5 was titrated 1:2 and showed a sigmoidal dose–
response to augmenting RV1b-induced IFNl1 mRNA at 24 h post-infection. (c) Mac5 was titrated 1:2 and showed a sigmoidal dose–response to
augmenting RV1b-induced IFNl2/3 mRNA at 24 h post-infection. (d) Mac5 was titrated 1:2 and showed a sigmoidal dose–response to augmenting
RV1b-induced MxA mRNA at 24 h post-Mac was titrated 1:2 and showed a sigmoidal dose–response to augmenting RV1b-induced viperin mRNA at
24 h post-infection. Data expressed as percentage change of RV1b+vehicle (VEH) (100% indicated by horizontal broken line). n¼3.
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Mac5AD). The acyl ureas and directly attached heterocyclic ureas
(e.g. Mac5E, Mac5O, Mac5T, Mac5Wand Mac5AA) tended to show
weaker activity as a class in the assays.
Discussion
Asthma, COPD and more recently CF are respiratory diseases that
are exacerbated by respiratory virus infections.24,35–39 The under-
lying aetiology is complex, but involves overzealous inflamma-
tion,24,37,40 – 42 bacterial colonization38 and impaired antiviral
immunity.16,24,29 In this study, we identified several new macro-
lides with virus-induced IFN-augmenting properties, with add-
itional anti-inflammatory and antibacterial potential. These
small molecules may be useful chemical starting points for future
drug discovery campaigns for new therapies for asthma, COPD
and also CF exacerbations.
One major challenge in drug discovery is selecting a reprodu-
cible readout in the screening phase that is biologically relevant
to the desired host’s response in vivo. In the present study, we
have combined immortalized cell lines and a luciferase-based
screening assay with studies in relevant (asthmatic) disease
cells to confirm findings. The ability to firstly measure IFN
responses to virus infection by screening a library of molecules
coupled with quick validation experiments in primary cells pro-
vides an extremely powerful means to identify novel drugs with
unique antiviral activity. Models of RV infection in BECs show virus-
dependent induction of IFN that correlate with increases in the
ISGs MxA and viperin43–45 and direct antiviral activity;16,20 there-
fore, detection of IFN production serves as viable surrogate read-
out of antiviral activity through induction of ISG pathways.
Furthermore, Mac5 reduced virus replication, proving antiviral
activity for both viruses tested. Mac5 reduced RV release in 7/10
asthmatic BECs tested, confirming that Mac5 does have antiviral
potential.
Previously, a promoter-linked bioluminescent detection assay
as a method of detecting promoter activity in a high-throughput
screen of small molecules was employed as a robust way of ana-
lysing a diverse library of compounds in a cost- and time-effective
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Figure 7. Novel macrolides demonstrated limited antibacterial activity against E. coli and respiratory pathogens compared with azithromycin. (a) E. coli
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manner.46 The use of immortalized cell lines to generate initial
data allows a scaling down of experiments to increase throughput
in a timely manner. We found using the IFNb promoter in reporter
assays a useful tool to screen macrolides and identified several
interestingmolecules using this system.We thought it was essen-
tial, however, to verify findings seen in immortalized cell lines in a
more clinically relevant model such as primary cell culture and
made use of both normal and asthmatic BECs to do so. As inher-
ent differences may exist between the two models, confirmatory
studies in primary cells are mandatory. This important point is
underscored in our study by the fact that despite identifying five
macrolides that augmented IFNb and IFNl1 promoter activation,
only one (Mac5) consistently induced endogenous mRNA in pri-
mary BECs. There are many reasons why the reporter-based
assay identified somany false positives byanalysis of endogenous
genes. BEAS-2B cells are an immortalized human bronchiolar cell
line and may exhibit subtle differences from normal primary BECs
(primary cells from cadavers) in response to both macrolide com-
pounds and virus infection. Additionally, in this study we looked at
mRNA expression at 24 h in BECs; due to the transient nature of
mRNA within cells, examining mRNA expression at a single time-
point provided only a snapshot of the effects of the novel
macrolides. This is kinetically different from the accumulation of
stable luciferase protein produced from promoter activation
over the course of 24 h (as in phases 1 and 2 of the screen) and
thusmayexplain why the BECs yielded different results to those in
the first two phases. Assessing the effects of macrolides on
BEC-derived gene transcription over the course of 24 h may con-
firm previous non-augmenters to indeed have IFN-augmenting
ability, but with amore limited duration of action and a peak aug-
menting effect at a time other than 24 h.
A limited number of studies have also previously identified
small molecules that are capable of augmenting host antiviral
responses to viruses.47–49 In theory, such small molecules cap-
able of boosting the host’s antiviral responses to viral infection
could prove to be an effective alternative to recombinant IFN ther-
apy in the prophylactic treatment of virally associated asthma or
COPD exacerbations.25 IFN production in response to viral infec-
tion is typically initiated by the activation of host cell PRRs such
as Toll-like receptors (TLRs).43 Several potent TLR agonists have
been reported that have antiviral activity and other immunomo-
dulatory properties.50 Previously, R-837 (imiquimod), a TLR7/8
agonist, was shown to be antiviral against herpes simplex
virus47 and human papilloma virus infection and is currently
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approved for use as a topical antiviral therapy for genital warts.48
We believe that azithromycin and the novel macrolides we have
identified such as Mac5 are unlikely to be functioning as TLR ago-
nists. An important difference between macrolides and TLR ago-
nists is that the macrolides did not induce IFN without infection,
but rather augmented IFN during infection. While their mechan-
ism(s) of action are unknown, this may give important clues as to
their function. It is possible that azithromycin and Mac5 ‘prime’
the IFN gene expression or ISG pathway, such that when infection
occurs, a greater magnitude and duration of IFN expression
occurs. Further studies, however, are required to understand the
mechanism of action of azithromycin and Mac5.
The ability to augment virus-induced IFN rather than spontan-
eously induce IFN in the absence of infection may also have
0.00
0.25
0.50
0.75
1.00
1.25
P.
 a
er
ug
in
os
a 
gr
ow
th
 a
t O
D 6
00
0.0
0.5
1.0
1.5
(a)
(b)
(c)
S.
 p
ne
um
on
ia
e 
gr
ow
th
 a
t O
D 6
00
* * * * * * * * * * *
0.0
0.5
1.0
1.5
N
HT
i g
ro
w
th
 a
t O
D 6
00
* * ** *** ****** *
VE
H
M
ac
5
M
ac
5A
M
ac
5B
M
ac
5C
M
ac
5D
M
ac
5E
M
ac
5F
M
ac
5G
M
ac
65
H
M
ac
5I
M
ac
5J
M
ac
5K
M
ac
5L
M
ac
5M
M
ac
5N
M
ac
5O
M
ac
5P
M
ac
5Q
M
ac
5R
M
ac
5S
M
ac
5T
M
ac
5U
M
ac
5V
M
ac
5W
M
ac
5X
M
ac
5Y
M
ac
5Z
M
ac
5A
A
M
ac
5A
B
M
ac
5A
C
M
ac
5A
D
AZ
M
VE
H
M
ac
5
M
ac
5A
M
ac
5B
M
ac
5C
M
ac
5D
M
ac
5E
M
ac
5F
M
ac
5G
M
ac
5H
M
ac
5I
M
ac
5J
M
ac
5K
M
ac
5L
M
ac
5M
M
ac
5N
M
ac
5O
M
ac
5P
M
ac
5Q
M
ac
5R
M
ac
5S
M
ac
5T
M
ac
5U
M
ac
5V
M
ac
5W
M
ac
5X
M
ac
5Y
M
ac
5Z
M
ac
5A
A
M
ac
5A
B
M
ac
5A
C
M
ac
5A
D
AZ
M
VE
H
M
ac
5
M
ac
5A
M
ac
5B
M
ac
5C
M
ac
5D
M
ac
5E
M
ac
5F
M
ac
5G
M
ac
5H
M
ac
5I
M
ac
5J
M
ac
5K
M
ac
5L
M
ac
5M
M
ac
5N
M
ac
5O
M
ac
5P
M
ac
5Q
M
ac
5R
M
ac
5S
M
ac
5T
M
ac
5U
M
ac
5V
M
ac
5W
M
ac
5X
M
ac
5Y
M
ac
5Z
M
ac
5A
A
M
ac
5A
B
M
ac
5A
C
M
ac
5A
D
AZ
M
Figure 9. Identification of novel analogues of Mac5 with varying antibacterial properties. Analogues of Mac5 were tested for antibacterial properties
against respiratory pathogens S. pneumoniae, P. aeruginosa and NTHi. (a) All novel Mac5 analogues (50 mM) showed antibacterial properties against
S. pneumoniae versus vehicle (VEH). Azithromycin (AZM; 50 mM) also showed significant activity. n¼3. (b) No Mac5 analogue showed any activity
against P. aeruginosa. AZM showed a suppressive, but not significant, effect versus VEH. n¼3. (c) Some Mac5 analogues showed activity against
NTHi. Mac5A, Mac5B, Mac5I, Mac5M, Mac5U, Mac5V, Mac5Y, Mac5AC and Mac5AD all had significant activity versus VEH. AZM also showed
significant activity. n¼3. *P,0.05, **P,0.01 and ***P,0.001 versus VEH.
New macrolides with IFN-augmenting potential
2777
JAC
 at Im
perial College of Science Technology and M
edicine on Septem
ber 26, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
some clinical advantages. Some trials with IFN as a therapy have
resulted in unwanted local inflammation and side effects.51 In cer-
tain systems, IFN is known to induce inflammation.52 As a therapy
for inflammatory disorders such as asthma and COPD, creating fur-
ther inflammation in the absence of infection may be detrimental
rather than beneficial. As azithromycin and othermacrolides do not
have this property, these side effects could in theory be avoided.
Other small molecules are known augmenters of IFN
induction. Thomas et al.49 have shown that ribavirin-treated
cells augment ISG responses in a model of hepatitis C virus infec-
tion. Furthermore, Patel et al.46 have described a novel high-
throughput screen that identified idarubicin, a small molecule
capable of augmenting the IFN signalling pathway in vitro leading
to increased ISG induction; however, this molecule has yet to be
tested in vivo. The ability to identify molecules with IFN-augment-
ing characteristics in a high-throughput, biologically relevant
screen and confirm action in primary cells is thus a powerful
tool for drug discovery and may provide future novel therapies
for the treatment of RV-associated asthma exacerbations as
well as other viral infections.
Several macrolides have recently been assessed as a therapy
for asthma and COPD exacerbations.53 While efficacy has varied
possibly due to macrolide-specific effects, patient selection and
study design, overall they provide encouraging evidence that
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macrolides can reduce the frequency, severity or duration of
exacerbations. A current scientific debate concerning macrolide
therapy is their mechanism of action. As azithromycin and cla-
rithromycin are believed to have antiviral, antibacterial and anti-
inflammatory properties, how they control exacerbations is likely
complex. Telithromycin has also shown efficacy in controlling
asthma exacerbations,54 yet has no known antiviral activity.28
As the clinical studies conducted with macrolides are not
designed to understand mechanisms, it is unclear whether or
not they are working via one or more of these properties. A recent
concern highlighted by such studies is their associated side
effects, particularly with azithromycin,55 which may be class
specific. While the antibacterial properties of macrolides may
in part explain their effectiveness in controlling exacerbations,
issues such as long-term use leading to bacterial resistance56 or
perturbing the natural microbiome57,58 have been raised, there-
fore perhaps contradicting their usefulness as treatments for
exacerbations. The discovery of macrolides that do not have
broad-spectrum antibacterial properties, but retain antiviral and
anti-inflammatory properties, may represent a forward step in
the design of next-generation macrolide-based therapies for
asthma and COPD exacerbations. Of interest, pandemic influenza
infection is also associated with an overabundance of inflamma-
tory cytokine production59 and this is associated with disease
severity.60 Macrolides with anti-inflammatory and IFN-boosting
potential may be useful in pandemic influenza infection also.
We examined antibacterial properties of the novel macrolides
firstly using E. coli as amodel organism and thenwith the important
respiratory pathogens S. pneumoniae, P. aeruginosa and NTHi.
Macrolides such as azithromycin promote their antibacterial effects
by binding to the large 50S ribosomal subunit in the narrow part of
the nascent peptide exit tunnel, thus blocking protein synthesis.61–63
For azithromycin and erythromycin, the macrolide ring as well as
the sugar moiety (desosamine) at position C5 both make exten-
sive bonds with the E. coli peptide exit tunnel.61,63,64 We found
that Mac26, an azithromycin derivative that had no antibacterial
properties in any culture tested including S. pneumoniae, has one
substitution on desosamine, in that the 2′-OH group has been
converted into an acetate and this hydroxyl group is thought to
stabilize macrolide–ribosome interactions.64 The erythromycin
derivatives Mac162, Mac202 and Mac206 also all had no antibac-
terial effects accept for the Gram-positive S. pneumoniae and
while other than having slight alterations in stereochemistry, des-
osamine was chemically the same in these compounds when
compared with erythromycin. There were several important sub-
stitutions in the 14-membered macrolide ring at positions C10
and C11, however, that could account for a lack of antibacterial
effects for Gram-negatives. Less is known about how oleandomy-
cin interacts with bacterial ribosomes. Mac5 differed from olean-
domycin by having a hydroxyl group changed into an acetate on
the macrocylic ring at C11 and a methyl benzyl urea on the sugar
oleandrose. An NMR study of oleandomycin and derivatives
thereof showed that positions C10–C12 make extensive interac-
tions with the ribosome;65 thus, it is possible that the hydroxyl–
acetate substitution at C11 affects this interaction and explains
the lack of effect on the Gram-negatives studied.
We further have identified macrolides with (Mac5AC and
Mac5AD) and without (Mac5 and Mac5K) antibacterial proper-
ties towards Gram-negatives, yet similar antiviral and anti-
inflammatory activity. The phenyl ureas Mac5, Mac5K, Mac5Q
and Mac5AB all had no antibacterial activity against the
Gram-negative bacteria we studied, while all the benzene or
methylene heterocyclic ureas with the exception of Mac5R had
some level of antibacterial activity. Mac5 having no activity
against Gram-negatives and the oleandomycin derivatives
Mac5H, Mac5YandMac5ADall shared acetates at C11, suggesting
that this alone does not account for changes in Gram-negative
antibacterial activity. In this report, we offer a brief description
of the chemistry of our novel macrolides, but a full investigation
into their structure–activity relationship (SAR) was beyond the
scope of this study. Further experiments are required to tease
out which functional groups are responsible for anti-inflammatory,
antibacterial and antiviral activity and, importantly, whether all
three functions are due to purely physiochemical properties.
These studies are thus among the first to show that these three
properties can be selected for in the same molecule and, although
a full SAR was not ascertained, we have shown that modest
changes in structure can alter the biological properties of the mol-
ecule. Themacrolideswe have identified therefore represent poten-
tial useful future alternatives to standardmacrolides for asthma, CF
and COPD exacerbations. We speculate that during an acute
exacerbation, a macrolide with all three properties may be initially
beneficial, controlling both viral and bacterial infections and the
associated inflammation; however, for longer-term use, a similar
macrolide that lacks broad-spectrum antibacterial, but similar
antiviral and anti-inflammatory, properties could be administered,
subverting bacterial resistance. The future management of
asthma, COPD and CF exacerbations may benefit from a selective
approach using a set of similarmacrolides, butwith specific tailored
properties.
In summary, we have used a semi-high-throughput reporter-
based assay to identify new macrolides with virus-induced IFN-
augmenting potential. One macrolide, Mac5, showed increased
efficacy and potency compared with a known macrolide, azithro-
mycin. Further studies identified several analogues of Mac5 with
various antiviral, anti-inflammatory and even broad-spectrum
antibacterial properties. These studies are among the first to high-
light the versatility ofmacrolides and underscore their potential as
antiviral, antibacterial and anti-inflammatory molecules. This
study has also identified several structures that may serve as
chemical starting points for future drug discovery campaigns
into new therapies for asthma, COPD and CF exacerbations.
Further SAR studies and specific interactions are required to fully
understand the multiple biological properties of these molecules.
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